Loading...
•
Sep 30, 2022
Centessa Q3 2022 Earnings Report
Centessa Pharmaceuticals reported financial results and business highlights.
Key Takeaways
Centessa Pharmaceuticals reported a net loss of $53.9 million for the third quarter of 2022, with cash and cash equivalents of $444.8 million as of September 30, 2022. The company is advancing its pivotal program for SerpinPC, planning to present Phase 2a OLE study data at ASH, and on track to submit the IND for LB101 in late 2022. The cash runway is expected to fund operations into 2026.
Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 observation study on track to begin this quarter.
Data readout of SerpinPC Phase 2a OLE Study with additional 18-months of continued subcutaneous treatment at ASH Annual Meeting in December 2022.
IND submission for LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody, on track for late 2022.
Cash runway into 2026 enables multiple clinical readouts across pipeline.
Centessa
Centessa
Forward Guidance
Centessa Pharmaceuticals expects its cash and cash equivalents to fund operations into 2026.